Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands

Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands

Gene transfer is a promising drug delivery method of advanced therapeutic entities for Parkinson's disease. One advantage over conventional therapies, such as peripheral delivery of the dopamine pre-cursor l-DOPA, is site-specific expression of proteins with regenerative, disease-modifying and...

Full description

Bibliographic Details
Main Authors:	Deniz Kirik, Erik Cederfjäll, Glenda Halliday, Åsa Petersén
Format:	Article
Language:	English
Published:	Elsevier 2017-01-01
Series:	Neurobiology of Disease
Subjects:	Adeno-associated virus AAV Viral vectors Non-human primates GDNF Neurturin
Online Access:	http://www.sciencedirect.com/science/article/pii/S0969996116302224

Similar Items

The Future of GDNF in Parkinson's Disease
by: Fredric P. Manfredsson, et al.
Published: (2020-12-01)

Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease
by: Pia Runeberg-Roos, et al.
Published: (2016-12-01)

Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system
by: Pedro Barroso-Chinea, et al.
Published: (2016-04-01)

Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain
by: Erik Cederfjäll, et al.
Published: (2012-11-01)

The intersection of vector biology, gene therapy, and hemophilia
by: Leszek Lisowski, et al.
Published: (2021-08-01)

Thermal Stability as a Determinant of AAV Serotype Identity
by: Antonette Bennett, et al.
Published: (2017-09-01)

Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease
by: Shilpa Ramaswamy, et al.
Published: (2007-05-01)

Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)
by: Christopher D. Herzog, et al.
Published: (2013-10-01)

Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors
by: Juliane Kuklik, et al.
Published: (2021-08-01)

Biology of Adeno-Associated Viral Vectors in the Central Nervous System
by: Giridhar eMurlidharan, et al.
Published: (2014-09-01)

Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies
by: Andreas L. Gimpel, et al.
Published: (2021-03-01)

Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease
by: Julia Tereshchenko, et al.
Published: (2014-05-01)

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease
by: Mehdi Gasmi, et al.
Published: (2007-07-01)

Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette
by: Sandeep R.P. Kumar, et al.
Published: (2021-12-01)

Treatment of Parkinson’s disease using focused ultrasound with GDNF retrovirus-loaded microbubbles to open the blood–brain barrier
by: Wang Feng, et al.
Published: (2020-08-01)

Pre-α-pro-GDNF and Pre-β-pro-GDNF Isoforms Are Neuroprotective in the 6-hydroxydopamine Rat Model of Parkinson's Disease
by: Anna-Maija Penttinen, et al.
Published: (2018-06-01)

Gene therapy for Huntington's disease
by: Shilpa Ramaswamy, et al.
Published: (2012-11-01)

Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases
by: Prabhakar Bastola, et al.
Published: (2020-08-01)

Ultrasound-Triggered Effects of the Microbubbles Coupled to GDNF Plasmid-Loaded PEGylated Liposomes in a Rat Model of Parkinson's Disease
by: Peijian Yue, et al.
Published: (2018-04-01)

AAV vectors for FRET-based analysis of protein-protein interactions in photoreceptor outer segments
by: Elvir Becirovic, et al.
Published: (2016-07-01)

Toward Development of Neuron Specific Transduction After Systemic Delivery of Viral Vectors
by: Dylan J. Finneran, et al.
Published: (2021-08-01)

AAV-CRB2 protects against vision loss in an inducible CRB1 retinitis pigmentosa mouse model
by: Thilo M. Buck, et al.
Published: (2021-03-01)

Diverse Effects of DNA Repair Pathways on the Outcome of Recombinant Adeno-Associated Virus (rAAV) Vector Gene Delivery
by: Cataldi, Marcela Patricia
Published: (2011)

A role for adeno-associated viral vectors in gene therapy
by: Renata dos Santos Coura, et al.
Published: (2008-01-01)

NaCl and KCl mediate log increase in AAV vector particles and infectious titers in a specific/timely manner with the HSV platform
by: Chenghui Yu, et al.
Published: (2021-06-01)

CERE-120 Prevents Irradiation-Induced Hypofunction and Restores Immune Homeostasis in Porcine Salivary Glands
by: Isabelle M.A. Lombaert, et al.
Published: (2020-09-01)

Planet of the AAVs: The Spinal Cord Injury Episode
by: Katerina Stepankova, et al.
Published: (2021-05-01)

Non-toxic HSC Transplantation-Based Macrophage/Microglia-Mediated GDNF Delivery for Parkinson’s Disease
by: Cang Chen, et al.
Published: (2020-06-01)

Cone Phosphodiesterase-6γ’ Subunit Augments Cone PDE6 Holoenzyme Assembly and Stability in a Mouse Model Lacking Both Rod and Cone PDE6 Catalytic Subunits
by: Wen-Tao Deng, et al.
Published: (2018-07-01)

Biology of GDNF and its receptors — Relevance for disorders of the central nervous system
by: Carlos F. Ibáñez, et al.
Published: (2017-01-01)

Modelling Non-motor Symptoms of Parkinson’s Disease: AAV Mediated Overexpression of Alpha-synuclein in Rat Hippocampus and Basal Ganglia
by: Sevgi Uğur Mutluay, et al.
Published: (2020-12-01)

Preclinical Assessment of Immune Responses to AAV (adeno-associated virus) Vectors
by: Etiena eBasner-Tschakarjan, et al.
Published: (2014-02-01)

Recombinant Adeno-Associated Virus Serotype 6 (rAAV6) Potently and Preferentially Transduces Rat Astrocytes in vitro and in vivo
by: Alexandra L. Schober, et al.
Published: (2016-11-01)

Adeno-Associated Virus (AAV) Gene Delivery: Dissecting Molecular Interactions upon Cell Entry
by: Edward E. Large, et al.
Published: (2021-07-01)

Intravitreal Co-Administration of GDNF and CNTF Confers Synergistic and Long-Lasting Protection against Injury-Induced Cell Death of Retinal Ganglion Cells in Mice
by: Simon Dulz, et al.
Published: (2020-09-01)

Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease
by: Ludovico Arcuri, et al.
Published: (2016-05-01)

A possible role of GDNF expression by which cabergoline use affects corpus callosum
by: Georgios Mitsiakos, et al.
Published: (2018-12-01)

Long-term, stable, targeted biodelivery and efficacy of GDNF from encapsulated cells in the rat and Goettingen miniature pig brain
by: Lars U. Wahlberg, et al.
Published: (2020-04-01)

Therapeutic Delivery of Butyrylcholinesterase by Brain-Wide Viral Gene Transfer to Mice
by: Yang Gao, et al.
Published: (2017-07-01)

Characterization of AAV-Specific Affinity Ligands: Consequences for Vector Purification and Development Strategies
by: Mario Mietzsch, et al.
Published: (2020-12-01)